Platelet Agregation in Patients on ECMO

University Medical Centre Ljubljana

Status: Enrolling

Conditions: Platelet Refractoriness

Treatments: Diagnostic Test: P2Y12 Platelet Aggregation Inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT05542134

KOIIM-UM

Details and patient eligibility

About

An observational study in which investigators will observe platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor.

Full description

Investigators will perform an observational study in which platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor will be observed.

Participants will be divided into three groups:

A: patients on V-A ECMO without P2Y12 inhibitors B patients on V-A ECMO with P2Y12 inhibitors with administration of P2Y12 inhibitor at the time of ECMO insertion C: patients on V-A ECMO already recieving P2Y12 inhibitors at the time of ECMO insertion.

Blood samples will be taken prior to and at 2, 4, 12, 22, 48, 72 after ECMO insertion and after removal of an ECMO. VerifyNow System will be used to measure platelet agregation (PRU test).

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all patients on VA ECMO

Exclusion criteria

• known P2Y12 alergy
• thrombocitopenic patents (< 50*109/L),
• patients treated with eptifibatide ali bivalirudin
• patients younger than 18 years
• pregnant patients

Trial design

50 participants in 3 patient groups

V-A ECMO without P2Y12 inhibitors

Description:

control group

Treatment:

Diagnostic Test: P2Y12 Platelet Aggregation Inhibitor

V-A ECMO with P2Y12 inhibitor at the time of ECMO

Description:

observational group 1

Treatment:

Diagnostic Test: P2Y12 Platelet Aggregation Inhibitor

V-A ECMO already recieving P2Y12 inhibitors

Description:

observational group 2

Treatment:

Diagnostic Test: P2Y12 Platelet Aggregation Inhibitor